Management of Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer

被引：41

作者：

Sacher, Adrian G. ^{[1
,2
]}

Jaenne, Pasi A. ^{[1
,3
,4
,5
]}

Oxnard, Geoffrey R. ^{[1
,4
,5
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA

[4] Brigham & Womens Hosp, Dept Thorac Oncol, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

来源：

CANCER | 2014年 / 120卷 / 15期

基金：

美国国家卫生研究院;

关键词：

non-small cell lung cancer; targeted therapy; epidermal growth factor receptor (EGFR); acquired resistance; BRAIN RADIATION-THERAPY; MET AMPLIFICATION; EGFR MUTATIONS; GENE-MUTATIONS; NONINVASIVE DETECTION; GEFITINIB RESISTANCE; 1ST-LINE GEFITINIB; ERLOTINIB; CHEMOTHERAPY; METASTASES;

D O I：

10.1002/cncr.28723

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The widespread adoption of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the first-line treatment of patients with advanced EGFR-mutated non-small cell lung cancer has resulted in acquired tyrosine kinase inhibitor resistance becoming a ubiquitous clinical problem. The identification of specific mechanisms of acquired resistance has allowed a better understanding of the biology and natural history of resistant disease, but is only now starting to impact treatment decisions. Strategies for managing acquired resistance in patients with advanced non-small cell lung cancer are complex and must be adapted to the individual characteristics of each patient's cancer. Although combination chemotherapy is the presumed standard of care for most patients, prospective trial data are lacking, highlighting the importance of offering patients participation in clinical trials in this setting. Emerging data from trials of third-generation mutant-specific EGFR kinase inhibitors suggests particular promise with this class of agents. (C) 2014 American Cancer Society.

引用

页码：2289 / 2298

页数：10